A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

Status: Recruiting
Phase: Phase 1
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT02014116 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:

 

The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Massachusetts General Hospital

Overall PI:
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Keith Flaherty, MD, Massachusetts General Hospital

Contacts:
Dana-Farber Cancer Institute: Andrew Wolanski, 617-632-6623, andrew_wolanski@dfci.harvard.edu

Eligibility Criteria

Inclusion Criteria: - Advanced or metastatic cancer - Other available therapies have failed to cure the cancer - The cancer that has no proven effective therapy - The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required) - Able to swallow capsules Exclusion Criteria: - Have active cancer in the brain or spinal cord - Have an active infection of any kind (fungal, viral, or bacterial) - Have a cancer of the blood - Are pregnant or breastfeeding - Have some types of eye problems or impairments
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms